Cerity Partners
ACAD icon

Cerity Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Cerity Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359K Sell
14,182
-1,590
-10% -$35K ﹤0.01% 2666
2026
Q1 		$351K Sell
15,772
-11,957
-43% -$286K ﹤0.01% 2501
2025
Q4 		$741K Sell
27,729
-6,834
-20% -$163K ﹤0.01% 1861
2025
Q3 		$738K Buy
34,563
+18,620
+117% +$440K ﹤0.01% 1750
2025
Q2 		$344K Sell
15,943
-644
-4% -$12K ﹤0.01% 2073
2025
Q1 		$276K Sell
16,587
-3,872
-19% -$70.3K ﹤0.01% 2064
2024
Q4 		$349K Buy
20,459
+6,173
+43% +$99.6K ﹤0.01% 1962
2024
Q3 		$220K Buy
+14,286
New +$238K ﹤0.01% 2260
2024
Q2 		– Sell
-12,992
Closed -$240K – 2222
2024
Q1 		$240K Buy
+12,992
New +$322K ﹤0.01% 1999
2021
Q3 		– Sell
-15,664
Closed -$382K – 684
2021
Q2 		$382K Sell
15,664
-5,000
-24% -$113K 0.01% 519
2021
Q1 		$533K Buy
20,664
+15,000
+265% +$660K 0.01% 438
2020
Q4 		$303K Buy
+5,664
New +$281K 0.01% 515

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cerity Partners's ACAD Position: Q2 2026 in Review

Cerity Partners reduced its Acadia Pharmaceuticals (ACAD) stake by 10% in Q2 2026, selling an estimated $35K and leaving 14,182 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

Cerity Partners first reported a position in ACAD in Q4 2020 and has held it in 12 quarters since. The position peaked at $741K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Cerity Partners held 14,182 shares of Acadia Pharmaceuticals worth $359K as of Q2 2026.
  • Cerity Partners sold 1,590 Acadia Pharmaceuticals shares in Q2 2026, an estimated $35K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2666 holding.
  • Cerity Partners first reported a position in Acadia Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
  • Cerity Partners's Acadia Pharmaceuticals position peaked at $741K in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.